BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11242714)

  • 1. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
    Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
    J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control.
    Mughal MA; Jan M; Maheri WM; Memon MY; Ali M
    J Pak Med Assoc; 2000 Nov; 50(11):381-6. PubMed ID: 11126815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of glibenclamide on serum lipids and lipoproteins in type II non-insulin dependent diabetes mellitus.
    Mughal MA; Maheri WM; Aamir K; Jan M; Ali M
    J Pak Med Assoc; 1999 Apr; 49(4):89-92. PubMed ID: 10540537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
    Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
    Sieradzki J; Soszyński P
    Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
    Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
    Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
    Li C; Hung YJ; Qamruddin K; Aziz MF; Stein H; Schmidt B
    Diabetes Res Clin Pract; 2011 Apr; 92(1):57-64. PubMed ID: 21251726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Güvener N; Gedik O
    Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
    Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT
    Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients.
    Ybarra J; James RW; Makoundou V; Bioletto S; Golay A
    Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients.
    Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.